Compare SINTX Technologies, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 11 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-1.43
-234.73%
2.65
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Dec 2025)
Net Profit:
-2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-27.68%
0%
-27.68%
6 Months
-47.86%
0%
-47.86%
1 Year
-11.42%
0%
-11.42%
2 Years
-86.16%
0%
-86.16%
3 Years
12.28%
0%
12.28%
4 Years
306.74%
0%
306.74%
5 Years
43.02%
0%
43.02%
SINTX Technologies, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.02%
EBIT Growth (5y)
-5.92%
EBIT to Interest (avg)
-10.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.35
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
17.56%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.65
EV to EBIT
-0.50
EV to EBITDA
-0.54
EV to Capital Employed
-2.86
EV to Sales
3.92
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-234.73%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 2 Schemes (1.31%)
Foreign Institutions
Held by 5 Foreign Institutions (0.31%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
0.30
0.20
50.00%
Operating Profit (PBDIT) excl Other Income
-2.20
-3.20
31.25%
Interest
0.00
0.00
Exceptional Items
0.00
-0.20
100.00%
Consolidate Net Profit
-2.20
-3.50
37.14%
Operating Profit Margin (Excl OI)
-7,993.10%
-16,129.80%
813.67%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 50.00% vs 0.00% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 37.14% vs -52.17% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1.00
2.90
-65.52%
Operating Profit (PBDIT) excl Other Income
-10.10
-7.70
-31.17%
Interest
0.10
0.00
Exceptional Items
-0.10
-2.10
95.24%
Consolidate Net Profit
-10.40
-11.00
5.45%
Operating Profit Margin (Excl OI)
-10,531.40%
-3,130.60%
-740.08%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -65.52% vs 11.54% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 5.45% vs -32.53% in Dec 2024
About SINTX Technologies, Inc. 
SINTX Technologies, Inc.
Pharmaceuticals & Biotechnology
SINTX Technologies, Inc., formerly Amedica Corporation, is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company is incorporating its silicon nitride technology into components for use in total hip and knee replacement product candidates. The Company markets and sells its products to surgeons and hospitals in the United States, and certain markets in Europe and South America. The Company produces silicon nitride for use in its commercial products and product candidates in the various forms, such as solid silicon nitride, porous silicon nitride, composite silicon nitride and silicon nitride coating.
Company Coordinates 
Company Details
1885 West 2100 Street , SALT LAKE CITY UT : 84119
Registrar Details






